Create a free account to see ACCE Scores
Sign up for free to unlock scores, score breakdowns, and stock analysis.
PRAX
↓ PDF (Pro)Praxis Precision Medicines Inc. Common Stock
HealthcareBiotechnologyUnited StatesNASDAQ
$333.55
+0.08%today
MKT CAP
$9.3B
-3.3% · 1Y
Earnings History
-2.5%
+1.4%
+3.7%
-12.0%
Q1 '25
Q2 '25
Q3 '25
Q4 '25
Analyst Targets
Current price
$333.55
Low
$130.00
Analyst Mean
$634.65
High
$1245.00
17 analystsStrong Buy
Full Financials
Trailing P/E-
Forward P/E-38.8x
EV/EBITDA-
Price/Sales-
Dividend Yield-
Revenue Growth YoY-
Earnings Growth YoY-
Revenue Growth QoQ-
5y Revenue CAGR-
5y Earnings CAGR-
Gross Margin-
Operating Margin-
Net Margin-
ROE-
Debt / Equity-
Free Cash Flow-
Insider Ownership0.3%
Institutional Ownership106.1%
Short % of Float13.59%
Days to Cover8.8d
1 Week+2.5%
1 Month-
3 Months-
6 Months-
YTD-
1 Year-
3 Years-
5 Years-
vs 50-day SMA-
vs 200-day SMA-
vs 52w High-
vs 52w Low-
Insider Transactions
| Filer | Role | Type | Shares | Price | Value | Date |
|---|---|---|---|---|---|---|
| KINDLER JEFFREY B | Director | Stock | 1,166 | $0.00 | $0.00M | 2026-02-06 |
| ARBUCKLE STUART A | Director | Stock | 1,166 | $0.00 | $0.00M | 2026-02-06 |
| SOUZA MARCIO SILVA DE | Chief Executive Officer | Stock | 27,640 | $0.00 | $0.00M | 2026-01-08 |
| SNIECINSKI MEGAN | Chief Operating Officer | Stock | 9,625 | $0.00 | $0.00M | 2026-01-08 |
| MASTROCOLA LAUREN | Officer | Stock | 3,750 | $0.00 | $0.00M | 2026-01-08 |
Top Holders
| Holder | Type | % Held | Value | Δ Shares | As of |
|---|---|---|---|---|---|
| Janus Henderson Group PLC | institution | 11.62% | $1.09B | +17.23% | 2025-12-31 |
| Blackrock Inc. | institution | 7.46% | $0.70B | +15.40% | 2025-12-31 |
| Perceptive Advisors Llc | institution | 7.16% | $0.67B | +27.58% | 2025-12-31 |
| Vanguard Group Inc | institution | 5.24% | $0.49B | +15.28% | 2025-12-31 |
| FMR, LLC | institution | 4.87% | $0.46B | +3044.28% | 2025-12-31 |
| Orbis Allan Gray Ltd | institution | 4.50% | $0.42B | +100.00% | 2025-12-31 |
| Baker Bros. Advisors, LP | institution | 4.04% | $0.38B | +63.38% | 2025-12-31 |
| Adage Capital Partners GP L.L.C. | institution | 3.46% | $0.33B | -59.34% | 2025-12-31 |
| Cormorant Asset Management, LP | institution | 3.41% | $0.32B | -5.00% | 2025-12-31 |
| Driehaus Capital Management, LLC | institution | 3.35% | $0.31B | +86.41% | 2025-12-31 |
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | fund | 2.83% | $0.27B | +17.25% | 2025-12-31 |
| iShares Trust-iShares Russell 2000 ETF | fund | 2.24% | $0.21B | +4.73% | 2026-03-31 |
| JANUS INVESTMENT FUND-Janus Henderson Global Life Sciences Fund | fund | 1.56% | $0.15B | +13.40% | 2025-12-31 |
| Fidelity Select Portfolios-Select Biotechnology Portfolio | fund | 1.40% | $0.13B | +0.00% | 2026-02-28 |
| SPDR SERIES TRUST-State Street SPDR S&P Biotech ETF | fund | 1.07% | $0.10B | -19.82% | 2026-03-31 |
| JANUS INVESTMENT FUND-Janus Henderson Enterprise Fund | fund | 1.04% | $0.10B | +100.00% | 2026-03-31 |
| VANGUARD INDEX FUNDS-Vanguard Extended Market Index Fund | fund | 0.91% | $0.09B | +18.78% | 2025-12-31 |
| JANUS INVESTMENT FUND-Janus Henderson Triton Fund | fund | 0.87% | $0.08B | -1.23% | 2026-03-31 |
| Fidelity Salem Street Trust-Fidelity Small Cap Index Fund | fund | 0.86% | $0.08B | +1.09% | 2026-02-28 |
| T. Rowe Price Health Sciences Fund, Inc. | fund | 0.82% | $0.08B | -6.00% | 2025-12-31 |
| Ticker | Cap | Score | P/E | Fwd P/E | EV/EBITDA | ROE | Gross | D/E | Div |
|---|---|---|---|---|---|---|---|---|---|
| CYTK | $9.3B | - | - | - | - | - | - | - | 0.00% |
| ABVX | $10.0B | 5 | - | - | - | - | - | - | 0.00% |
| IBRX | $8.7B | 5 | - | - | - | - | - | - | 0.00% |
| KRYS | $8.4B | 31 | 38.1 | 27.9 | - | - | - | - | 0.00% |
| PCVX | $8.2B | 5 | - | - | - | - | - | - | 0.00% |
| BMRN | $10.5B | 49 | 38.9 | 8.1 | 15.3 | 4.5% | 51% | 23.17 | 0.00% |
Peers selected by sector + industry + nearest market cap. Best in column highlighted green, worst red.
Unlock Full Financials
Growth metrics, valuation multiples, and profitability ratios on Starter+.
Recent Alerts
No alerts yet for PRAX.
Want deep analysis?
This stock isn't in the ACCE researched universe. Browse 300+ stocks with full thesis, scores, and financial models.
Browse ACCE Indices →Get the ACCE weekly digest
Index returns, picks recap, score movers - every Sunday. No fluff.